Answer
Yes, haemophagocytic lymphohistiocytosis, including fatal cases, has been reported in patients receiving mosunetuzumab (Lunsumio).
Sources for this answer
- Lunsumio 1 mg and 30 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 10Document updated
Sources checked